CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0203
Issued: 2026-09-09

PRODUCT IDENTIFICATION

PRODUCT NAD+	SKU / INTERNAL CODE CRF-2026-0203	PRESENTATION Lyophilised powder, 500 mg vial
BATCH NUMBER CRF-2026-0203	SAMPLE RECEIVED 2026-09-03	PRODUCTION DATE 2026-08-28
ANALYSIS DATE 2026-09-07	EXPIRY / RETEST DATE 2028-09-07	MOLECULAR FORMULA (REFERENCE) C21H27N7O14P2
MOLECULAR WEIGHT (G/MOL; REFERENCE) 663.43	CAS (REFERENCE) 53-84-9	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Shimadzu LC-20AD	COLUMN C18 4.6×150mm	COLUMN TEMPERATURE 30°C
MOBILE PHASE A 0.1% Formic Acid	MOBILE PHASE B MeOH	FLOW RATE 1.0 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 10 µL	SAMPLE CONCENTRATION 1.0 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 4.8 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.6%	PASS
Identity (Method not recorded)	663.4 ±2%	Obs: 665.4 [M+H]+	PASS
Quantity found	95.0–105.0%	498.0 mg (99.6%)	PASS
Endotoxin	<1.0 EU/mg	<0.5 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: High-purity coenzyme, free of nicotinamide degradation products.

crafa

CRAFA